Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening

Key facts

Sponsor

Medical University of Vienna

Intervention

CBMed Drug Screening Plattform(diagnostic_test)

Enrollment

240 enrolled

Eligibility

18-75 years · All sexes

Timeline

2024 – 2031

Study locations (1)

• AKH Vienna, Department for Internal Medicine I, Oncology, Vienna, Austria

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07326566
  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
  Black Diamond Therapeutics, Inc.
• RECRUITINGPHASE1, PHASE2NCT07501559
  A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
  Jecho Biopharmaceuticals Co., Ltd.
• RECRUITINGPHASE1NCT07464925
  A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
  Tetragon Biosciences Ltd
• RECRUITINGNCT07411690
  Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors
  Medical University of Warsaw
• RECRUITINGPHASE1NCT07480941
  Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
  Beijing Biotech
• RECRUITINGPHASE2NCT07225621
  Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
  Alpheus Medical, Inc.
• RECRUITINGPHASE1, PHASE2NCT07391215
  5G-PEARL: Paxalisib in Malignant Brain Tumours
  Institute of Cancer Research, United Kingdom
• RECRUITINGNANCT07426848
  OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients
  Royal College of Surgeons, Ireland

See all trials for Glioblastoma →